OnwardMobility Announces Agreements with BlackBerry and Foxconn Subsidiary FIH Mobile to Bring BlackBerry 5G Smartphones to Market
OnwardMobility today announced agreements with BlackBerry (NYSE: BB; TSX:BB) and FIH Mobile Limited (HKG: 2038), a subsidiary of Foxconn Technology Group, to deliver a new 5G BlackBerry Android smartphone with physical keyboard, in the first half of 2021 in North America and Europe. Under the terms of the agreement, BlackBerry grants OnwardMobility the right to develop, engineer, and bring to market a BlackBerry 5G mobile device. Working closely with OnwardMobility, BlackBerry and FIH Mobile will ensure world-class design and manufacturing of these devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200819005202/en/
With the increasing number of employees working remotely with critical data and applications, coupled with the constant threat of cyberattacks, there is an absolute need for a secure, feature-rich 5G-ready phone that enhances productivity. Employees are demanding better workplace technology experiences, and organizations are facing increasingly complex challenges in selecting, deploying, securing and managing devices to meet expectations and maximize employee productivity.
“Enterprise professionals are eager for secure 5G devices that enable productivity, without sacrificing the user experience,” said Peter Franklin, CEO of OnwardMobility. “BlackBerry smartphones are known for protecting communications, privacy, and data. This is an incredible opportunity for OnwardMobility to bring next-generation 5G devices to market with the backing of BlackBerry and FIH Mobile.”
“Companies are rapidly investing in transformative technologies to improve productivity, but often don’t place enough emphasis on security, particularly in their use of mobile devices,” said analyst Jack Gold, President and Principal Analyst of J. Gold Associates, LLC. “With 5G quickly coming to market, and the acceleration it will cause in upgrading mobile devices and deploying productivity enhancing apps, deploying proven and highly secure products like the BlackBerry 5G devices in enterprises, government, and regulated industries like finance or legal, are mission critical."
“BlackBerry is thrilled OnwardMobility will deliver a BlackBerry 5G smartphone device with physical keyboard leveraging our high standards of trust and security synonymous with our brand. We are excited that customers will experience the enterprise and government level security and mobile productivity the new BlackBerry 5G smartphone will offer,” said John Chen, Executive Chairman and CEO, BlackBerry.
OnwardMobility will conduct product planning and market development for BlackBerry smartphones in North America and FIH Mobile will design and manufacture the BlackBerry devices under strict guidelines to ensure component, device and supply chain integrity.
“As an exclusive supplier to OnwardMobility, we’re committed to delivering new BlackBerry 5G devices to market, utilizing our deep expertise in design, manufacturing, component supply and logistics management,” said Dr. Wen-Yi Kuo, Executive Director, FIH Mobile.
Interested in learning more about OnwardMobility? Please visit: onwardmobility.com
- Potential financial partners may email: FinancialPartners@OnwardMobility.com.
- Businesses interested in ensuring access to early production or in pre-ordering devices may email: Contact@OnwardMobility.com.
- Those interested in working with OnwardMobility to solve today’s pressing security challenges may send resumes to: Recruiting@OnwardMobility.com.
OnwardMobility is dedicated to producing the most productive, user-friendly and secure mobile devices for all businesses, from government to enterprise to those who power the gig economy. Security shapes every process involved in the development, design, supply chain sourcing and manufacture of all OnwardMobility devices. Our team is comprised of industry veterans and serial entrepreneurs with deep mobile, government and enterprise expertise. To learn more about our corporate mission, please visit: https://onwardmobility.com/ or follow us on Twitter, Facebook and LinkedIn.
About FIH Mobile Limited
As a subsidiary of Foxconn Technology Group and a leader in the mobile device industry worldwide, FIH offers a vertically integrated design, development, and manufacturing services, that is a comprehensive range of end-to-end engineering services and manufacturing services to its customers in respect of handsets, mobile/wireless communication devices and consumer electronic products. In light of moving into Internet era and exploring new business opportunities, FIH has also been engaged in 5G, IoV (Internet of Vehicle) and AI for building up the Internet and the mobile ecosystem. Visit our website at http://www.fihmb.com/
BlackBerry (NYSE: BB; TSX: BB) provides intelligent security software and services to enterprises and governments around the world. The company secures more than 500M endpoints including 175M cars on the road today. Based in Waterloo, Ontario, the company leverages AI and machine learning to deliver innovative solutions in the areas of cybersecurity, safety and data privacy solutions, and is a leader in the areas of endpoint security management, encryption, and embedded systems. BlackBerry’s vision is clear - to secure a connected future you can trust. For more information, visit BlackBerry.com and follow @BlackBerry.
Marianne Dempsey, 617-233-8675
Jenna Beaucage, 508-340-6851
Michelle McMahon, 781-718-3248
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom